A Phase II Study of MK 2206 in Patients With Relapsed or Refractory Diffuse Large B Cell Lymphoma.
Phase of Trial: Phase II
Latest Information Update: 05 Aug 2015
At a glance
- Drugs MK 2206 (Primary)
- Indications Diffuse large B cell lymphoma
- Focus Therapeutic Use
- Acronyms AKTIL
- 03 Jan 2014 Status changed from recruiting to discontinued, reported by ClinicalTrials.gov (NCT01466868).
- 03 Jan 2014 Planned End Date changed from 1 May 2015 to 1 May 2014, reported by ClinicalTrials.gov (NCT01466868).
- 11 Jan 2012 Actual initiation date changed from Dec 2011 to Nov 2011 as reported by ClinicalTrials.gov.